株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

網膜静脈閉塞症:パイプライン製品の分析

Retinal Vein Occlusion - Pipeline Review, H2 2017

発行 Global Markets Direct 商品コード 192808
出版日 ページ情報 英文 90 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.42円で換算しております。
Back to Top
網膜静脈閉塞症:パイプライン製品の分析 Retinal Vein Occlusion - Pipeline Review, H2 2017
出版日: 2017年11月30日 ページ情報: 英文 90 Pages
概要

網膜静脈閉塞症は、網膜の静脈のいずれかが閉塞して血管が詰まって血液が流れなくなる病気です。網膜では、像が神経信号に変換されます。主な症状は、無痛性の突然の視力変化です。素因として、アテローム性動脈硬化症、黄斑浮腫、糖尿病、高血圧、高コレステロール、年齢などが挙げられます。

当レポートでは、網膜静脈閉塞症に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

網膜静脈閉塞症の概要

治療薬の開発

  • パイプライン製品の概要

網膜静脈閉塞症:企業で開発中の治療薬

網膜静脈閉塞症:パイプライン製品の概況

  • 臨床段階の製品
  • 初期段階の製品

網膜静脈閉塞症:企業で開発中の製品

網膜静脈閉塞症の治療薬開発に従事している企業

  • Aerpio Therapeutics, Inc.
  • Avalanche Biotechnologies, Inc.
  • EyeGate Pharmaceuticals, Inc.
  • Kala Pharmaceuticals, Inc.
  • Mabion SA
  • NicOx S.A.
  • Ohr Pharmaceutical Inc.
  • Precision Ocular Ltd
  • pSivida Corp.
  • ThromboGenics NV

網膜静脈閉塞症:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

網膜静脈閉塞症:最近のパイプライン動向

網膜静脈閉塞症:休止中のプロジェクト

網膜静脈閉塞症:開発が中止された製品

網膜静脈閉塞症:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9947IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Retinal Vein Occlusion - Pipeline Review, H2 2017, provides an overview of the Retinal Vein Occlusion (Ophthalmology) pipeline landscape.

Retinal vein occlusion is a blockage in one of the veins returning blood flow from the retina. The retina is where images are converted to nerve signals. The primary symptom of retinal vein occlusion is a sudden painless change in vision. Predisposing factors are atherosclerosis, macular edema, diabetes, high blood pressure, high cholesterol and age.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Retinal Vein Occlusion - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Retinal Vein Occlusion (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Retinal Vein Occlusion (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Retinal Vein Occlusion and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 3, 3, 9, 2 and 1 respectively.

Retinal Vein Occlusion (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Retinal Vein Occlusion (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Retinal Vein Occlusion (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Retinal Vein Occlusion (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Retinal Vein Occlusion (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Retinal Vein Occlusion (Ophthalmology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Retinal Vein Occlusion (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Retinal Vein Occlusion (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Retinal Vein Occlusion - Overview
    • Retinal Vein Occlusion - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Retinal Vein Occlusion - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Retinal Vein Occlusion - Companies Involved in Therapeutics Development
    • Acucela Inc
    • Addmedica SAS
    • Aerpio Therapeutics Inc
    • Annexin Pharmaceuticals AB
    • Chengdu Kanghong Pharmaceuticals Group Co Ltd
    • Clearside BioMedical Inc
    • Formycon AG
    • Graybug Vision Inc
    • Kala Pharmaceuticals Inc
    • Lupin Ltd
    • Mabion SA
    • Novartis AG
    • Ocular Therapeutix Inc
    • Ohr Pharmaceutical Inc
    • Regeneron Pharmaceuticals Inc
    • SciFluor Life Sciences LLC
    • ThromboGenics NV
  • Retinal Vein Occlusion - Drug Profiles
    • ACU-6151 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • aflibercept biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • aflibercept biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • aflibercept SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AKB-9778 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AP-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • conbercept - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HO-10 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hydroxyurea - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KPI-285 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LKA-651 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ocriplasmin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OTX-TKI - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Protein to Inhibit VEGF for Ophthalmology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ranibizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ranibizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ranibizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SF-0166 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • squalamine lactate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sunitinib malate CR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • triamcinolone acetonide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Retinal Vein Occlusion - Dormant Projects
  • Retinal Vein Occlusion - Discontinued Products
  • Retinal Vein Occlusion - Product Development Milestones
    • Featured News & Press Releases
      • Jun 08, 2017: Clearside Biomedical's TANZANITE Extension Study in Patients with Macular Edema Associated with Retinal Vein Occlusion Presented at the 40th Annual Macula Society Meeting
      • Feb 16, 2017: Clearside Biomedical Announces First Patient Randomized in Phase 3 Clinical Trial of Zuprata Used Together With Eylea in Subjects With Retinal Vein Occlusion
      • Oct 10, 2016: Clearside Biomedical to Report Clinical Trial Results at 2016 Retina Sub-Specialty Day Meeting at the American Academy of Ophthalmology (AAO) Meeting
      • Jul 26, 2016: Clearside Biomedical Announces Patient Treatment Comparison from the Phase 2 Trial (TANZANITE) in Patients with Macular Edema Associated with Retinal Vein Occlusion
      • Apr 26, 2016: Clearside Biomedical Announces Positive Preliminary Phase 2 Results in Patients With Macular Edema Associated with Retinal Vein Occlusion
      • Dec 14, 2015: Clearside Biomedical Completes Enrollment in Phase 2 Clinical Trial of CLS-TA for the Treatment of Retinal Vein Occlusion Using Suprachoroidal Space Drug Administration
      • Jul 13, 2015: Ohr Pharmaceutical Announces Positive Results of a Phase II Clinical Study for OHR-102 in Retinal Vein Occlusion
      • Apr 23, 2015: ThromboGenics Starts Evaluating JETREA for the Treatment of Retinal Vein Occlusion
      • Aug 11, 2014: Ohr Pharmaceutical Announces Squalamine Eye Drop (OHR-102) Phase II Clinical Data in Retinal Vein Occlusion
      • Aug 20, 2013: Ohr Pharmaceutical Announces Investigator Sponsored Trial of Squalamine Eye Drops in Retinal Vein Occlusion
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Retinal Vein Occlusion, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Retinal Vein Occlusion - Pipeline by Acucela Inc, H2 2017
  • Retinal Vein Occlusion - Pipeline by Addmedica SAS, H2 2017
  • Retinal Vein Occlusion - Pipeline by Aerpio Therapeutics Inc, H2 2017
  • Retinal Vein Occlusion - Pipeline by Annexin Pharmaceuticals AB, H2 2017
  • Retinal Vein Occlusion - Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, H2 2017
  • Retinal Vein Occlusion - Pipeline by Clearside BioMedical Inc, H2 2017
  • Retinal Vein Occlusion - Pipeline by Formycon AG, H2 2017
  • Retinal Vein Occlusion - Pipeline by Graybug Vision Inc, H2 2017
  • Retinal Vein Occlusion - Pipeline by Kala Pharmaceuticals Inc, H2 2017
  • Retinal Vein Occlusion - Pipeline by Lupin Ltd, H2 2017
  • Retinal Vein Occlusion - Pipeline by Mabion SA, H2 2017
  • Retinal Vein Occlusion - Pipeline by Novartis AG, H2 2017
  • Retinal Vein Occlusion - Pipeline by Ocular Therapeutix Inc, H2 2017
  • Retinal Vein Occlusion - Pipeline by Ohr Pharmaceutical Inc, H2 2017
  • Retinal Vein Occlusion - Pipeline by Regeneron Pharmaceuticals Inc, H2 2017
  • Retinal Vein Occlusion - Pipeline by SciFluor Life Sciences LLC, H2 2017
  • Retinal Vein Occlusion - Pipeline by ThromboGenics NV, H2 2017
  • Retinal Vein Occlusion - Dormant Projects, H2 2017
  • Retinal Vein Occlusion - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Retinal Vein Occlusion, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top